<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121172">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02106871</url>
  </required_header>
  <id_info>
    <org_study_id>13-0409</org_study_id>
    <nct_id>NCT02106871</nct_id>
  </id_info>
  <brief_title>Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer</brief_title>
  <acronym>PCC</acronym>
  <official_title>Phase I Assessment of NO Mediated Signaling in Cancer Cachexia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas, Galveston</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blinded, placebo-controlled trial in men and women, 40-75 years old,
      diagnosed with pancreatic or cholangiocarcinoma cancer. Patients will receive placebo or
      sildenafil daily for 4 weeks during their initial chemotherapy cycle.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Lean Body Mass</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Lean body mass will be measured by DEXA scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skeletal Muscle Fatigue</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Skeletal muscle fatigue will be measured by leg dynamometer.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sildenafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50mg sildenafil daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>50mg of Sildenafil daily for 4 weeks</description>
    <arm_group_label>Sildenafil</arm_group_label>
    <other_name>Viagra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women, aged 40-75 years.

          2. Diagnosed with Stage III or IV pancreatic or cholangiocarcinoma receiving the
             following therapy:

               -  Neoadjuvant chemotherapy

               -  Surgical resection followed by chemotherapy.

          3. Able to comprehend risks and sign a consent form.

          4. Performance Status of 0-2.

        Exclusion Criteria:

          1. Significant renal or heart disease or any acute metabolic disease.

          2. Evidence of hepatitis as indicated by a 3-fold increase in of 2 out of 3 liver
             enzymes.

          3. Diabetes mellitus or other untreated endocrine disease.

          4. Recent (within 3 months) treatment with anabolic steroids.

          5. Ongoing anticoagulant therapy.

          6. Androgen secreting tumors of the ovary and adrenal or any ovarian tumor (e.g.,
             Sertoli-Leydig).

          7. Polycystic ovary syndrome (PCOS) and/or hyperthecosis.

          8. Non-classical adrenal hyperplasia.

          9. Cushing's syndrome.

         10. Glucocorticoid resistance.

         11. Pregnancy.

         12. Hyperprolactinoma, hypothyroidism.

         13. Use of nitrates.

         14. Use of alpha blockers.

         15. Use of protease inhibitors.

         16. Use of cytochrome p450 inhibitors.

         17. Systolic blood pressure &lt;100 or &gt;150, diastolic blood pressure &lt;60 or &gt;90.  This
             range is smaller than the acceptable range stated in the prescribing information for
             sildenafil (&gt;90/50 and &lt;170/110).

         18. Peripheral vascular disease.

         19. Use of a phosphodiesterase 5 inhibitor.

         20. Any other circumstance deemed exclusionary by the PI or study physician.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melinda Sheffield-Moore, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kate M Randolph, BS</last_name>
    <phone>409-772-8126</phone>
    <email>kmrandol@utmb.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christopher Danesi, MS</last_name>
    <phone>409-772-8126</phone>
    <email>cpdanesi@utmb.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Randolph, BS</last_name>
      <phone>409-772-8126</phone>
      <email>kmrandol@utmb.edu</email>
    </contact>
    <investigator>
      <last_name>Melinda Sheffield-Moore, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>April 3, 2014</lastchanged_date>
  <firstreceived_date>January 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas, Galveston</investigator_affiliation>
    <investigator_full_name>Melinda Sheffield Moore</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>pancreas</keyword>
  <keyword>cholangiocarcinoma</keyword>
  <keyword>fatigue</keyword>
  <keyword>sildenafil</keyword>
  <keyword>lean mass</keyword>
  <keyword>muscle</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sildenafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
